Coherus BioSciences (CHRS) Misses Q2 EPS by 60c
Tweet
Share
E-mailGet Alerts CHRS Hot Sheet
Price: $1.48 --0%
EPS Growth %: +23.5%
Financial Fact:
Depreciation and amortization: 14.21M
Today's EPS Names:
OCCI, MAYS, CRMT, More
EPS Growth %: +23.5%
Financial Fact:
Depreciation and amortization: 14.21M
Today's EPS Names:
OCCI, MAYS, CRMT, More
Join SI Premium – FREE
Coherus BioSciences (NASDAQ: CHRS) reported Q2 EPS of ($1.71), $0.60 worse than the analyst estimate of ($1.11). Revenue for the quarter came in at $844 thousand, versus $10.2 million reported last year.
For earnings history and earnings-related data on Coherus BioSciences (CHRS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Ridgepost Capital acquires Stellus Capital Management for $4B AUM
- Stifel Reiterates Buy Rating on FedEx (FDX) Ahead of Q4 Earnings
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
